Rani Therapeutics Holdings (RANI) Receivables (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Receivables of $2.0 million for Q4 2025, up 146.62% year-over-year from $828000.0 in Q4 2024, and up 240.33% quarter-over-quarter from $600000.0 in Q1 2025.
Rani Therapeutics Holdings (RANI) Receivables (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Receivables history runs 3 years deep, the most recent figure standing at $2.0 million for Q4 2025.
- In Q4 2025, Receivables rose 146.62% year-over-year to $2.0 million; the TTM figure through Dec 2025 stood at $2.0 million (up 146.62% YoY), while the FY2025 annual figure was $2.0 million, up 146.62% from the prior year.
- Receivables for Q4 2025 stood at $2.0 million, up from $600000.0 in the prior quarter.
- The five-year high for Receivables was $2.0 million in Q4 2025, with the low at $600000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | 2.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.04 Mn |
| Mar 31, 2026 | 2.04 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 828,000.00 |
| Dec 31, 2020 | 1.72 Mn |